Novartis finally completes Alcon buy
This article was originally published in Clinica
Executive Summary
Novartis has completed its acquisition of eyecare specialist Alcon, after shareholders approved the proposed takeover, worth $51.6bn in total, earlier today. Alcon's shareholders gave the acquisition the green light yesterday.